Insider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Sells $176,600.00 in Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Gregory M. Weinhoff sold 10,000 shares of the company’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $17.66, for a total value of $176,600.00. Following the completion of the sale, the insider now owns 183,266 shares of the company’s stock, valued at $3,236,477.56. This represents a 5.17 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Centessa Pharmaceuticals Stock Performance

CNTA opened at $17.91 on Friday. The company has a market cap of $2.36 billion, a P/E ratio of -11.71 and a beta of 1.47. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The firm’s 50-day moving average price is $16.20 and its 200-day moving average price is $12.60. Centessa Pharmaceuticals plc has a 52-week low of $5.58 and a 52-week high of $18.74.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.05. As a group, equities analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 EPS for the current fiscal year.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD grew its stake in Centessa Pharmaceuticals by 16.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,958,079 shares of the company’s stock valued at $33,427,000 after purchasing an additional 418,615 shares during the last quarter. Nantahala Capital Management LLC acquired a new stake in shares of Centessa Pharmaceuticals during the second quarter worth about $4,064,000. Driehaus Capital Management LLC boosted its position in Centessa Pharmaceuticals by 89.5% in the second quarter. Driehaus Capital Management LLC now owns 2,092,011 shares of the company’s stock valued at $18,891,000 after buying an additional 987,997 shares during the last quarter. GSA Capital Partners LLP increased its holdings in Centessa Pharmaceuticals by 66.1% in the 3rd quarter. GSA Capital Partners LLP now owns 93,658 shares of the company’s stock worth $1,498,000 after buying an additional 37,275 shares during the period. Finally, First Light Asset Management LLC raised its position in Centessa Pharmaceuticals by 59.2% during the 2nd quarter. First Light Asset Management LLC now owns 4,780,560 shares of the company’s stock worth $43,168,000 after buying an additional 1,778,515 shares during the last quarter. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on CNTA shares. Oppenheimer reaffirmed an “outperform” rating and issued a $14.00 price objective on shares of Centessa Pharmaceuticals in a research note on Wednesday, August 14th. Morgan Stanley raised shares of Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $11.00 to $26.00 in a research report on Thursday, September 19th. BMO Capital Markets lifted their price objective on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a report on Monday, September 16th. Jefferies Financial Group upped their price objective on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, September 11th. Finally, Guggenheim increased their target price on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Friday, November 15th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Centessa Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $25.83.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.